Novartis AG

LSE:0QLR Stock Report

Market Cap: CHF 182.1b

Novartis Valuation

Is 0QLR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QLR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QLR (CHF91.06) is trading below our estimate of fair value (CHF243.2)

Significantly Below Fair Value: 0QLR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QLR?

Key metric: As 0QLR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QLR. This is calculated by dividing 0QLR's market cap by their current earnings.
What is 0QLR's PE Ratio?
PE Ratio17.5x
EarningsUS$11.76b
Market CapUS$206.30b

Price to Earnings Ratio vs Peers

How does 0QLR's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QLR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.1x
AZN AstraZeneca
30.3x18.0%UK£155.4b
GSK GSK
21.2x21.9%UK£53.2b
HIK Hikma Pharmaceuticals
18.1x12.8%UK£4.1b
ROG Roche Holding
18.8x11.1%CHF 201.3b
0QLR Novartis
17.5x7.0%CHF 182.1b

Price-To-Earnings vs Peers: 0QLR is good value based on its Price-To-Earnings Ratio (17.5x) compared to the peer average (22.1x).

Price to Earnings Ratio vs Industry

How does 0QLR's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0QLR 17.5xIndustry Avg. 20.8xNo. of Companies8PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QLR is good value based on its Price-To-Earnings Ratio (17.5x) compared to the European Pharmaceuticals industry average (20.6x).

Price to Earnings Ratio vs Fair Ratio

What is 0QLR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QLR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.5x
Fair PE Ratio33.8x

Price-To-Earnings vs Fair Ratio: 0QLR is good value based on its Price-To-Earnings Ratio (17.5x) compared to the estimated Fair Price-To-Earnings Ratio (33.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QLR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 91.06
CHF 103.07
+13.2%
9.5%CHF 120.95CHF 86.39n/a19
Nov ’25CHF 95.03
CHF 101.39
+6.7%
9.4%CHF 118.72CHF 84.80n/a19
Oct ’25CHF 97.39
CHF 99.03
+1.7%
9.1%CHF 114.46CHF 85.16n/a19
Sep ’25CHF 102.08
CHF 97.78
-4.2%
9.8%CHF 113.82CHF 80.50n/a20
Aug ’25CHF 98.46
CHF 101.16
+2.7%
10.3%CHF 118.70CHF 83.96n/a20
Jul ’25CHF 96.22
CHF 99.52
+3.4%
11.3%CHF 118.94CHF 76.04n/a20
Jun ’25CHF 93.17
CHF 98.24
+5.4%
10.8%CHF 117.30CHF 75.97n/a19
May ’25CHF 89.05
CHF 98.98
+11.1%
11.2%CHF 119.11CHF 74.61n/a18
Apr ’25CHF 86.89
CHF 97.95
+12.7%
11.5%CHF 115.90CHF 74.48n/a18
Mar ’25CHF 90.30
CHF 96.18
+6.5%
11.3%CHF 112.69CHF 73.48n/a18
Feb ’25CHF 89.93
CHF 94.50
+5.1%
11.1%CHF 109.90CHF 74.57n/a18
Jan ’25CHF 84.35
CHF 90.96
+7.8%
10.2%CHF 106.89CHF 73.97n/a18
Dec ’24CHF 85.60
CHF 91.69
+7.1%
10.7%CHF 108.52CHF 72.86n/a18
Nov ’24CHF 85.26
CHF 95.13
+11.6%
10.5%CHF 111.59CHF 75.42CHF 95.0318
Oct ’24CHF 94.11
CHF 102.41
+8.8%
10.9%CHF 118.23CHF 81.87CHF 97.3918
Sep ’24CHF 89.25
CHF 100.83
+13.0%
9.8%CHF 114.09CHF 81.59CHF 102.0818
Aug ’24CHF 91.07
CHF 99.49
+9.3%
10.1%CHF 112.21CHF 80.24CHF 98.4617
Jul ’24CHF 89.99
CHF 97.84
+8.7%
9.8%CHF 110.68CHF 79.87CHF 96.2216
Jun ’24CHF 87.96
CHF 97.81
+11.2%
9.3%CHF 111.76CHF 80.71CHF 93.1719
May ’24CHF 91.06
CHF 95.31
+4.7%
9.5%CHF 108.68CHF 80.63CHF 89.0519
Apr ’24CHF 83.75
CHF 90.78
+8.4%
10.5%CHF 107.30CHF 79.17CHF 86.8920
Mar ’24CHF 78.58
CHF 92.36
+17.5%
10.6%CHF 107.98CHF 70.40CHF 90.3021
Feb ’24CHF 81.60
CHF 88.37
+8.3%
10.1%CHF 103.42CHF 69.57CHF 89.9321
Jan ’24CHF 84.29
CHF 86.89
+3.1%
11.4%CHF 103.77CHF 69.93CHF 84.3521
Dec ’23CHF 84.03
CHF 86.17
+2.6%
10.7%CHF 101.83CHF 70.18CHF 85.6021
Nov ’23CHF 81.07
CHF 89.60
+10.5%
11.0%CHF 107.25CHF 69.99CHF 85.2621

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

hVIVO

UK£161.9m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.24

7D

-20.1%

1Y

31.3%

Formycon

€820.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.05

7D

-1.4%

1Y

-23.9%

Regeneron Pharmaceuticals

US$82.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$741.73

7D

-9.3%

1Y

-6.8%